150 related articles for article (PubMed ID: 8420183)
1. IBZM-SPECT imaging in Parkinson's disease. Quantification of binding ratios from sequential SPECT measurements in patients and controls.
Cordes M; Hierholzer J; Schelosky L; Poewe W; Cordes I; Horowski R; Eichstaedt H; Schmidt D; Felix R
Adv Neurol; 1993; 60():525-8. PubMed ID: 8420183
[No Abstract] [Full Text] [Related]
2. IBZM-SPECT as predictor for dopamimetic responsiveness of patients with de novo parkinsonian syndrome.
Oertel WH; Schwarz J; Tatsch K; Arnold G; Gasser T; Kirsch CM
Adv Neurol; 1993; 60():519-24. PubMed ID: 8420182
[TBL] [Abstract][Full Text] [Related]
3. 123I-beta-CIT and 123I-IBZM-SPECT scanning in levodopa-naive Parkinson's disease.
Wenning GK; Donnemiller E; Granata R; Riccabona G; Poewe W
Mov Disord; 1998 May; 13(3):438-45. PubMed ID: 9613734
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic value of asymmetric striatal D2 receptor upregulation in Parkinson's disease: an [123I]IBZM and [123I]FP-CIT SPECT study.
Verstappen CC; Bloem BR; Haaxma CA; Oyen WJ; Horstink MW
Eur J Nucl Med Mol Imaging; 2007 Apr; 34(4):502-7. PubMed ID: 17053905
[TBL] [Abstract][Full Text] [Related]
5. [123]IBZM binding predicts dopaminergic responsiveness in patients with parkinsonism and previous dopaminomimetic therapy.
Schwarz J; Tatsch K; Gasser T; Arnold G; Oertel WH
Mov Disord; 1997 Nov; 12(6):898-902. PubMed ID: 9399212
[TBL] [Abstract][Full Text] [Related]
6. [Dopamine (D2) receptor SPECT with 123I-iodobenzamide (IBZM) in diagnosis of Parkinson syndrome].
Reiche W; Grundmann M; Huber G
Radiologe; 1995 Nov; 35(11):838-43. PubMed ID: 8657887
[TBL] [Abstract][Full Text] [Related]
7. Loss of dopamine-D2 receptor binding sites in Parkinsonian plus syndromes.
Hierholzer J; Cordes M; Venz S; Schelosky L; Harisch C; Richter W; Keske U; Hosten N; Mäurer J; Poewe W; Felix R
J Nucl Med; 1998 Jun; 39(6):954-60. PubMed ID: 9627325
[TBL] [Abstract][Full Text] [Related]
8. A single photon emission computed tomography scan study of striatal dopamine D2 receptor binding with 123I-epidepride in patients with schizophrenia and controls.
Tibbo P; Silverstone PH; McEwan AJ; Scott J; Joshua A; Golberg K
J Psychiatry Neurosci; 1997 Jan; 22(1):39-45. PubMed ID: 9002391
[TBL] [Abstract][Full Text] [Related]
9. Long-term changes of striatal dopamine D2 receptors in patients with Parkinson's disease: a study with positron emission tomography and [11C]raclopride.
Antonini A; Schwarz J; Oertel WH; Pogarell O; Leenders KL
Mov Disord; 1997 Jan; 12(1):33-8. PubMed ID: 8990051
[TBL] [Abstract][Full Text] [Related]
10. Alterations of striatal dopamine D2 receptors contribute to deteriorated response to L-dopa in Parkinson's disease: a [123I]-IBZM SPET study.
Pizzolato G; Chierichetti F; Rossato A; Cagnin A; Fabbri M; Dam M; Ferlin G; Battistin L
J Neural Transm Suppl; 1995; 45():113-22. PubMed ID: 8748616
[TBL] [Abstract][Full Text] [Related]
11. [The determination of cerebral dopamine (D2) receptor density by using 123I-IBZM-SPECT in Parkinson disease patients].
Hierholzer J; Cordes M; Schelosky L; Barzen G; Poewe W; Henkes H; Keske U; Horowski R; Felix R
Rofo; 1992 Oct; 157(4):390-8. PubMed ID: 1391843
[TBL] [Abstract][Full Text] [Related]
12. Imaging of D2 dopamine receptors of patients with Parkinson's disease using single photon emission computed tomography and iodobenzamide I 123.
Laulumaa V; Kuikka JT; Soininen H; Bergström K; Länsimies E; Riekkinen P
Arch Neurol; 1993 May; 50(5):509-12. PubMed ID: 8489408
[TBL] [Abstract][Full Text] [Related]
13. [SPECT with 123I-IBZM: utility in differential diagnosis of degenerative Parkinsonisms and establishment of quantification method].
Poblete García V; García Vicente A; Ruíz Solís S; Martínez Delgado C; Vaamonde J; Rodado Marina S; Cortés Romera M; Talavera Rubio M; Ibáñez R; Soriano Castrejón A
Rev Esp Med Nucl; 2005; 24(4):234-43. PubMed ID: 16122407
[TBL] [Abstract][Full Text] [Related]
14. 123I-IBZM SPECT: reconstruction methodology and results in parkinsonism and dystonia.
Berding G; Gratz KF; Kolbe H; Meyer GJ; Dengler R; Knoop BO; Hundeshagen H
Nuklearmedizin; 1994 Oct; 33(5):194-9. PubMed ID: 7997377
[TBL] [Abstract][Full Text] [Related]
15. Striatal D2 dopamine receptor status in Parkinson's disease: an [18F]dopa and [11C]raclopride PET study.
Dentresangle C; Veyre L; Le Bars D; Pierre C; Lavenne F; Pollak P; Guerin J; Froment JC; Brousolle E
Mov Disord; 1999 Nov; 14(6):1025-30. PubMed ID: 10584682
[No Abstract] [Full Text] [Related]
16. Estimation of dopamine D2 receptor binding potential in the striatum with iodine-123-IBZM SPECT: technical and interobserver variability.
Verhoeff NP; Kapucu O; Sokole-Busemann E; van Royen EA; Janssen AG
J Nucl Med; 1993 Dec; 34(12):2076-84. PubMed ID: 8254390
[TBL] [Abstract][Full Text] [Related]
17. Iodine-123-iodobenzamide binding in parkinsonism: reduction by dopamine agonists but not L-Dopa.
Schwarz J; Oertel WH; Tatsch K
J Nucl Med; 1996 Jul; 37(7):1112-5. PubMed ID: 8965179
[TBL] [Abstract][Full Text] [Related]
18. Correlation of clinical response in apomorphine test with D2-receptor status as demonstrated by 123I IBZM-SPECT.
Schelosky L; Hierholzer J; Wissel J; Cordes M; Poewe W
Mov Disord; 1993 Oct; 8(4):453-8. PubMed ID: 8232354
[TBL] [Abstract][Full Text] [Related]
19. Kinetic analyses of [123I]IBZM SPECT for quantification of striatal dopamine D2 receptor binding: a critical evaluation of the single-scan approach.
Meyer PT; Sattler B; Winz OH; Fundke R; Oehlwein C; Kendziorra K; Hesse S; Schaefer WM; Sabri O
Neuroimage; 2008 Aug; 42(2):548-58. PubMed ID: 18595739
[TBL] [Abstract][Full Text] [Related]
20. [The differential diagnosis of Parkinson diseases--123I-IBZM-SPECT vs. the apomorphine test].
Hierholzer J; Cordes M; Schelosky L; Sander B; Böck JC; David I; Horowski R; Poewe W
Rofo; 1993 Jul; 159(1):86-90. PubMed ID: 8334264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
